From Th1 to Th2: Diabetes immunotherapy shifts gears

1. Tian, J. et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nature Med. 2, 1348−1353 (1996). | Article | PubMed  | ISI | ChemPort |
2. Harrison, L.C. Antigen-specific therapy for autoimmune disease: Prospects for the prevention of insulin-dependent diabetes. Molec. Med. 1, 722−727 (1995). | ISI | ChemPort |
3. Verge, C.F. et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512/IA-2 autoantibodies. Diabetes 45, 926−933 (1996). | PubMed  | ISI | ChemPort |
4. Tyden, G., Reinholt, F.P., Sundkvist, G. & Bolinder, J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N. Eng. J. Med. 335, 860−863 (1996). | Article | ISI | ChemPort |
5. Solimena, M. & De Camilli, P. Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci. 14, 452−457 (1991). | Article | PubMed  | ISI | ChemPort |
6. Kaufman, D.L. et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366, 69−72 (1993). | Article | PubMed  | ISI | ChemPort |
7. Tisch, R. et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366, 72−75 (1993). | Article | PubMed  | ISI | ChemPort |
8. Elliott, J.F. et al. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune disease in NOD mice. Diabetes 43, 1494−1499 (1994). | PubMed  | ISI | ChemPort |
9. Petersen, J.S. et al. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 43, 1478−1484 (1994). | PubMed  | ISI | ChemPort |
10. Pleau, J.M., Fernandez-Saravia, F., Esling, A., Homo-Delarche, F. & Dardenne, M. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin. Immunol. Immunopath. 76, 90−95 (1995). | Article | ISI | ChemPort |
11. Forsthuber, T., Yip, H.C. & Lehmann, P.V. Induction of TH1 and TH2 immunity in neonatal mice. Science 271, 1728−1730 (1996). | PubMed  | ISI | ChemPort |
12. Tian, J. et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. exp. Med. 183, 1561−1567 (1996). | Article | PubMed  | ISI | ChemPort |
13. Elias, D. & Cohen, I.R. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Lancet 343, 704−706 (1994). | Article | PubMed  | ISI | ChemPort |
14. Keller, R.J., Eisenbarth, G.S. & Jackson, R.A. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341, 927−928 (1993). | Article | PubMed  | ISI | ChemPort |
15. Haskins, K. & Wegmann, D. Diabetogenic T-cell clones. Diabetes 45, 1299−1305 (1996). | PubMed  | ISI | ChemPort |
16. Katz, J.D., Benoist, C. & Mathis, D. T helper cell subsets in insulin-dependent diabetes. Science 268, 1185−1188 (1995). | PubMed  | ISI | ChemPort |
17. Serreze, D.V., Leiter, E.H., Christianson, G.J., Greiner, D. & Roopenian, D.C. Major histocompatibility complex class I-deficient NOD B2-null mice are diabetes and insulitis resistant. Diabetes 43, 505−509 (1994). | PubMed  | ISI | ChemPort |
18. Wicker, L.S. et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 43, 505−509 (1994). | PubMed  | ISI | ChemPort |
19. Wong, F.S., Visintin, I., Wen, L., Flavell, R.A. & Janeway, C.A. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183, 67−76 (1996). | Article | PubMed  | ISI | ChemPort |

	Top

	Top